[ad_1]
WESTLAKE VILLAGE, Calif., February 25, 2021 (GLOBE NEWSWIRE) – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an advanced-stage biopharmaceutical company focused on the development and commercialization of treatments for unmet needs in dermatologic-mediated diseases Immune and Conditions, or Immunodermatology, today announced that Arcutis management will participate in a virtual presentation at the 41st Annual Cowen Healthcare Conference to be held March 1-4, 2021.
The details of the presentation are as follows:
Cowen 41st Annual Healthcare Conference
Date of presentation: Monday, March 1, 2021
Presentation time: 12:20 p.m. PT / 3:20 p.m. ET
The presentation will be webcast and can be viewed in the “Events and Presentations” section of the Company’s website at https://investors.arcutis.com/events-and-presentations. Arcutis will maintain an archived replay of the webcast on its website for 30 days after the conference.
About Arcutis – Bioscience, applied to the skin.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an advanced-stage biopharmaceutical company focused on the development and commercialization of treatments for unmet needs of immune-mediated dermatological diseases and conditions or immunodermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment problems in severe skin diseases. Arcutis’ strong pipeline includes four new drug candidates currently in development for a range of inflammatory dermatological diseases. The Company’s lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis and seborrheic dermatitis. For more information, visit https://www.arcutis.com or follow the company on LinkedIn and Twitter.
Investors and media:
Heather rowe armstrong
Vice-President, Investor Relations and Corporate Communications
[email protected]
805-418-5006, ext. 740
Source link
